Yuankai Shi1, Qingyuan Zhang2, Xiaohong Han1, Yan Qin1, Xiaoyan Ke3, Hang Su4, Li Liu5, Jinxiang Fu6, Jie Jin7, Jifeng Feng8, Xiaonan Hong9, Xiaohong Zhang10, Depei Wu11, Bin Jiang12, Xiaodong Dong13. 1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China. 2. Harbin Medical University Cancer Hospital, Harbin 150081, China. 3. Peking University Third Hospital, Beijing 100191, China. 4. The 307th Hospital of Military Chinese People's Liberation Army, Beijing 100071, China. 5. Tangdu Hospital of the Fourth Military Medical University, Xi'an 710038, China. 6. The Second Affiliated Hospital of Soochow University, Suzhou 215004, China. 7. The First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou 310006, China. 8. Jiangsu Cancer Hospital, Nanjing 210009, China. 9. Fudan University Shanghai Cancer Center, Shanghai 200032, China. 10. The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 310003, China. 11. The First Affiliated Hospital of Soochow University, Suzhou 215006, China. 12. Peking University People's Hospital, Beijing 100034, China. 13. Shanghai Henlius Biotech, Inc., Shanghai 200233, China.
Abstract
OBJECTIVE: This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01 (a rituximab biosimilar) and reference rituximab sourced from China (MabThera®; rituximab-CN). METHODS: Here we report the results of two phase 1 studies. In the phase 1a, open-label, dose-escalation study (NCT03218072, CTR20140400), eligible patients received 250, 375 and 500 mg/m2 HLX01 sequentially at 7-day intervals, after confirming no dose-limiting toxicity (DLT). In the phase 1b, double-blind study (NCT02584920, CTR20140764), eligible patients were given a single dose of 375 mg/m2 HLX01 or rituximab-CN. The primary endpoints included safety and tolerability parameters for the phase 1a and the area under the plasma concentration-time curve from time zero to day 91 (AUC0-91 d) for the phase 1b study. Equivalence was concluded if 90% confidence interval (90% CI) for the geometric least squares mean ratio (GLSMR) fell in the pre-specified equivalence criteria (80%-125%). RESULTS: Between June 20, 2014 and January 5, 2015, 12 patients were enrolled in the phase 1a study. The pharmacokinetics of HLX01 showed dose proportionality and accumulation to steady state. HLX01 was well tolerated, with no serious adverse events (AEs), discontinuations or DLTs. Between November 8, 2014 and August 13, 2015, 87 eligible patients were enrolled in the phase 1b study, including 43 who received HLX01 and 44 who were treated with rituximab-CN. The equivalence endpoint was met with GLSMR for AUC0-91 d being 89.6% (90% CI: 80.4%-99.8%). AEs, anti-drug antibodies, and CD19+ and CD20+ B lymphocyte counts were similar between the HLX01 and rituximab-CN treatment groups. CONCLUSIONS: Treatment with HLX01 was safe and well tolerated in Chinese patients with B-cell lymphoma. HLX01 and rituximab-CN have similar pharmacokinetic, pharmacodynamic and safety profiles.
OBJECTIVE: This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01 (a rituximab biosimilar) and reference rituximab sourced from China (MabThera®; rituximab-CN). METHODS: Here we report the results of two phase 1 studies. In the phase 1a, open-label, dose-escalation study (NCT03218072, CTR20140400), eligible patients received 250, 375 and 500 mg/m2 HLX01 sequentially at 7-day intervals, after confirming no dose-limiting toxicity (DLT). In the phase 1b, double-blind study (NCT02584920, CTR20140764), eligible patients were given a single dose of 375 mg/m2 HLX01 or rituximab-CN. The primary endpoints included safety and tolerability parameters for the phase 1a and the area under the plasma concentration-time curve from time zero to day 91 (AUC0-91 d) for the phase 1b study. Equivalence was concluded if 90% confidence interval (90% CI) for the geometric least squares mean ratio (GLSMR) fell in the pre-specified equivalence criteria (80%-125%). RESULTS: Between June 20, 2014 and January 5, 2015, 12 patients were enrolled in the phase 1a study. The pharmacokinetics of HLX01 showed dose proportionality and accumulation to steady state. HLX01 was well tolerated, with no serious adverse events (AEs), discontinuations or DLTs. Between November 8, 2014 and August 13, 2015, 87 eligible patients were enrolled in the phase 1b study, including 43 who received HLX01 and 44 who were treated with rituximab-CN. The equivalence endpoint was met with GLSMR for AUC0-91 d being 89.6% (90% CI: 80.4%-99.8%). AEs, anti-drug antibodies, and CD19+ and CD20+ B lymphocyte counts were similar between the HLX01 and rituximab-CN treatment groups. CONCLUSIONS: Treatment with HLX01 was safe and well tolerated in Chinese patients with B-cell lymphoma. HLX01 and rituximab-CN have similar pharmacokinetic, pharmacodynamic and safety profiles.
Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245
Authors: Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly Journal: Lancet Date: 2010-12-20 Impact factor: 79.321
Authors: D G Maloney; A J Grillo-López; D J Bodkin; C A White; T M Liles; I Royston; C Varns; J Rosenberg; R Levy Journal: J Clin Oncol Date: 1997-10 Impact factor: 44.544
Authors: Stanley Cohen; Paul Emery; Maria Greenwald; Donghua Yin; Jean-Claude Becker; Lisa Ann Melia; Ruifeng Li; Barry Gumbiner; Dolca Thomas; George Spencer-Green; Xu Meng Journal: Br J Clin Pharmacol Date: 2016-04-29 Impact factor: 4.335
Authors: Jon Thorkell Einarsson; Max Evert; Pierre Geborek; Tore Saxne; Maria Lundgren; Meliha C Kapetanovic Journal: Clin Rheumatol Date: 2017-10-04 Impact factor: 2.980
Authors: Dae Hyun Yoo; Chang-Hee Suh; Seung Cheol Shim; Slawomir Jeka; Francisco Fidencio Cons-Molina; Pawel Hrycaj; Piotr Wiland; Eun Young Lee; Francisco G Medina-Rodriguez; Pavel Shesternya; Sebastiao Radominski; Marina Stanislav; Volodymyr Kovalenko; Dong Hyuk Sheen; Leysan Myasoutova; Mie Jin Lim; Jung-Yoon Choe; Sang Joon Lee; Sung Young Lee; Taek Sang Kwon; Won Park Journal: Ann Rheum Dis Date: 2016-09-13 Impact factor: 19.103